About Artivion, Inc.
https://artivion.comArtivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo.
CEO
James Patrick Mackin
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-12-28 | Forward | 3:2 |
| 1996-07-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 147
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Canaccord Genuity
Buy
Needham
Buy
Stifel
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 7
Price Target
About Artivion, Inc.
https://artivion.comArtivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $113.39M ▲ | $61.86M ▼ | $6.5M ▲ | 5.73% ▲ | $0.14 ▲ | $18.89M ▲ |
| Q2-2025 | $112.97M ▲ | $64.73M ▲ | $1.34M ▲ | 1.19% ▲ | $0.03 ▲ | $16.29M ▲ |
| Q1-2025 | $98.98M ▲ | $61.43M ▲ | $-505K ▲ | -0.51% ▲ | $-0.01 ▲ | $10.81M ▲ |
| Q4-2024 | $97.31M ▲ | $58.83M ▲ | $-16.48M ▼ | -16.94% ▼ | $-0.39 ▼ | $-565K ▼ |
| Q3-2024 | $95.78M | $56.62M | $-2.29M | -2.39% | $-0.05 | $13.25M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $73.43M ▲ | $857.66M ▲ | $418.97M ▲ | $438.69M ▲ |
| Q2-2025 | $53.48M ▲ | $838.39M ▲ | $418.49M ▼ | $419.9M ▲ |
| Q1-2025 | $37.69M ▼ | $791.16M ▲ | $496.91M ▼ | $294.25M ▲ |
| Q4-2024 | $53.46M ▼ | $789.1M ▼ | $512.9M ▲ | $276.2M ▼ |
| Q3-2024 | $56.17M | $803.14M | $498.4M | $304.74M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $6.5M ▲ | $20.51M ▲ | $-4.61M ▼ | $4.07M ▲ | $19.95M ▲ | $15.9M ▲ |
| Q2-2025 | $1.34M ▲ | $15.01M ▲ | $-3.29M ▲ | $2.6M ▼ | $15.78M ▲ | $11.72M ▲ |
| Q1-2025 | $-505K ▲ | $-16.95M ▼ | $-3.64M ▲ | $3.94M ▲ | $-15.77M ▼ | $-20.59M ▼ |
| Q4-2024 | $-16.48M ▼ | $10.14M ▼ | $-11.43M ▼ | $174K ▼ | $-2.71M ▼ | $8.71M ▲ |
| Q3-2024 | $-2.29M | $11.46M | $-10.64M | $1.47M | $1.15M | $7.82M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Aortic Stent Grafts | $30.00M ▲ | $30.00M ▲ | $40.00M ▲ | $40.00M ▲ |
 On X | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $30.00M ▲ |
 Other Products | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Preservation Services | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $30.00M ▲ |
 Surgical Sealants | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
Revenue by Geography
| Region | Q3-2024 | Q4-2024 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Asia Pacific Segment | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Europe the Middle East and Africa Segments | $30.00M ▲ | $30.00M ▲ | $40.00M ▲ | $40.00M ▲ |
 Latin America Segment | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 North America Segment | $50.00M ▲ | $50.00M ▲ | $60.00M ▲ | $50.00M ▼ |
CEO
James Patrick Mackin
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-12-28 | Forward | 3:2 |
| 1996-07-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 147
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Canaccord Genuity
Buy
Needham
Buy
Stifel
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 7